Dr Reddy’s Pilots Sputnik V Soft Launch In India, Explores CAR-T Space
Dr Reddy’s initiates pilot roll-out of imported Russian vaccine Sputnik V, currently priced at about $13.50 per dose in India, and indicates that it hopes to bring the single-dose version Sputnik Light to the country. The Indian company also strikes a deal with a Chinese firm for a CAR-T cell therapy, an area where it hopes to “pick up skills”.
You may also be interested in...
Amid growing moves in India for local manufacturers to make and supply biosimilars, Shilpa’s biologics division has moved a step closer to becoming the first Indian company to initiate clinical trials for a biosimilar to Regeneron’s Eylea treatment for ophthalmic diseases.
Billionaire philanthropist and co-chair of the Bill and Melinda Gates Foundation signals efforts underway to support building mRNA capacity in India amid the new platform’s potential beyond COVID-19 vaccines. He also highlights the need to bring down sharply the cost of gene therapies.
Cipla is no novice in the vaccines segment and a potential link up for Moderna’s mRNA COVID-19 vaccine or with other firms could add an important lever in the 80-plus year-old Indian firm’s overall strategic thrust. Management has all along maintained a positive tone for coronavirus vaccine alliances.